CLRB vs PRTC vs RNAC vs RMD vs NUVL

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). ResMed Inc. (RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to -99. 2% for Cellectar Biosciences, Inc. (CLRB). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus CLRB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.

51β versus Cartesian Therapeutics, Inc. 's 2. 03β — meaning RNAC is approximately 299% more volatile than PRTC relative to the S&P 500. On balance sheet safety, Cellectar Biosciences, Inc. (CLRB) carries a lower debt/equity ratio of 4% versus 14% for ResMed Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). On earnings-per-share growth, the picture is similar: Cellectar Biosciences, Inc. grew EPS 80. 1% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, PRTC leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -46. 6% for Cartesian Therapeutics, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -31. 0% for RNAC. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTC: 235.

9% to $57. 00.

In this comparison, RMD (1.

0% yield) pays a dividend. CLRB, PRTC, RNAC, NUVL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RMD: +293. 8%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RMD pays a dividend while CLRB, PRTC, RNAC, NUVL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.